Tumor volumein insignificant prostate cancer: Increasing threshold gains increasing risk

Prostate

Volumn 75, Issue 1, 2015, Pages 45-49

  Schiffmann, Jonas ^a   Connan, Judith ^a   Salomon, Georg ^a   Boehm, Katharina ^a   Beyer, Burkhard ^a   Schlomm, Thorsten ^a   Tennstedt, Pierre ^a   Sauter, Guido ^a   Karakiewicz, Pierre I ^b   Graefen, Markus ^a   Huland, Hartwig ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Biochemical recurrence; Insignificant prostate cancer; Radical prostatectomy; Tumor volume

Indexed keywords

ADULT; ARTICLE; BIOCHEMICAL RECURRENCE FREE SURVIVAL; CANCER MORTALITY; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; PROSTATECTOMY; TUMOR VOLUME; AGED; DISEASE FREE SURVIVAL; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; PROSTATE; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK; SURVIVAL; TUMOR RECURRENCE;

AGED; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK; SURVIVAL ANALYSIS; TUMOR BURDEN;

EID: 84918786644     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22889     Document Type: Article

References (14)

1. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271 (5): 368-374.
2. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer. Relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993; 71 (3 Suppl): 933-938.
3. Ploussard G, Epstein JI, Montironi R, Carroll PR, Wirth M, Grimm MO, Bjartell AS, Montorsi F, Freedland SJ, Erbersdobler A, van der Kwast TH. The contemporary concept of significant versus insignificant prostate cancer. Eur Urol 2011; 60 (2): 291-303.
4. Wolters T, Roobol MJ, van Leeuwen PJ, van den Bergh RC, Hoedemaeker RF, van Leenders GJ, Schroder FH, van der Kwast TH. A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial. J Urol 2011; 185 (1): 121-125.
5. Gleason. Histological grading and staging of prostate carcinoma. In: Tannenbaum M, editor. The prostate. Philadelphia: Lea & Freiberger Urologic Pathology; 1977. pp. 171-198.
6. Carvalhal GF, Humphrey PA, Thorson P, Yan Y, Ramos CG, Catalona WJ. Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy. Cancer 2000; 89 (6): 1308-1314.
7. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, Wein A. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280 (11): 969-974.
8. Capitanio U, Ahyai S, Graefen M, Jeldres C, Shariat SF, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P, Peloquin F, Pharand D, Arjane P, Huland H, Karakiewicz PI. Assessment of biochemical recurrence rate in patients with pathologically confirmed insignificant prostate cancer. Urology 2008; 72 (6): 1208-1211, discussion 1212-1203.
9. Hashimoto Y, Okamoto A, Imai A, Yoneyama T, Hatakeyama S, Koie T, Kaminura N, Ohyama C. Biochemical outcome of smallvolume or insignificant prostate cancer treated with radical prostatectomy in Japanese population. Int J Clin Oncol 2012; 17 (2): 119-123.
10. Sengupta S, Blute ML, Bagniewski SM, Inman B, Leibovich BC, Slezak JM, Myers RP, Zincke H. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer. BJU Int 2008; 101 (2): 170-174.
11. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005; 29 (9): 1228-1242.
12. Bianco FJ Jr, Scardino PT, Eastham JA. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 2005; 66 (5 Suppl)83-94.
13. Ploussard G, Staerman F, Pierrevelcin J, Saad R, Beauval JB, Roupret M, Audenet F, Peyromaure M, Delongchamps NB, Vincendeau S, Fardoun T, Rigaud J, Villers A, Bastide C, SoulieM, Salomon L. Predictive factors of oncologic outcomes in patients who do not achieve undetectable prostate specific antigen after radical prostatectomy. J Urol 2013; 190 (5): 1750-1756.
14. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281 (17): 1591-1597.